Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

Medical Officer. "We continue to believe that interferon remains the greatest impediment to care for a majority of the millions of individuals living with HCV.  PSI-7977 has demonstrated high cure rates, without viral resistance, and across HCV genotypes; we hope to confirm these benefits in these registrational studies."

About FISSON

FISSION will be conducted at more than 100 centers in the US, Europe and other territories. The trial will enroll approximately 500 treatment-naive patients with HCV genotype 2 or 3 into one of two open-label regimens:

  • PSI-7977 400 mg QD with ribavirin for 12 weeks
  • the current standard-of-care for HCV GT2/3, pegylated interferon and ribavirin for 24 weeks

The study will include patients with and without cirrhosis, and will enroll a greater proportion of patients with HCV genotype 3, who are less likely to achieve an SVR with the currently available therapy, pegylated interferon and ribavirin.  The primary endpoint of the trial will be SVR12. Enrollment is anticipated to begin by the end of 2011.

About POSITRON

POSITRON will be conducted at more than 100 centers in the US, Europe and other territories.  The trial will enroll patients with HCV genotype 2 or 3 who cannot take interferon into one of two blinded regimens:

  • PSI-7977 400 mg QD with ribavirin for 12 weeks
  • placebo PSI-7977 and placebo ribavirin

POSITRON will enroll approximately 225 patients with or without cirrhosis.  The primary endpoint of the trial will be SVR12. Enrollment is anticipated to begin in the first quarter of 2012.

About NEUTRINO

NEUTRINO will enroll approximately 280 patients who cannot take interferon. The study will be conducted at more than 100 centers in the US, Europe and other territories. The final design of the trial will be based on em
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Feb. 28, 2011 PolyOne Corporation (NYSE: POL ... in SunBelt Chlor Alkali Partnership to Olin Corporation.   ... venture formed in 1996 between PolyOne (formerly The Geon Company) ... for $175 million, including $132 million in cash and the ...
... LOUIS, Feb. 28, 2011 Stereotaxis, Inc. (Nasdaq: ... full year and fourth quarter ended December 31, 2010. ... capital orders, record recurring revenue and record gross margins. ... the year, which helped to drive decreases in both ...
Cached Medicine Technology:PolyOne Announces Sale of SunBelt Investment 2PolyOne Announces Sale of SunBelt Investment 3Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 2Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 3Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 4Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 5Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 6Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 7
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Aug. 26 (HealthDay News) -- Two new European reports should ... diagnosing possible heart attacks in emergency room patients, cardiologists say. ... of the New England Journal of Medicine , looked ... cells. Standard practice in most hospitals now calls for a ...
... Tenn., Aug. 26 HCA today announced the start of its ... HCA CEO Richard Bracken, 125 not-for-profit agencies and more than 1,000 ... employee giving campaign this morning in Centennial Park. , , ... com.com/cgi-bin/prnh/20050825/CLTH069LOGO ) , , Last year, ...
... ... Generation and Gender Impact Physician Engagement", , ... Charlotte, NC (Vocus) August 26, 2009 -- Morehead , the human capital ... Engagement." The free hour-long webinar will be broadcast on Wednesday, September 16, 2009 at ...
... , , , , ... , , Medical group-specific cost information available at ... MINNEAPOLIS, Aug. 26 In a significant step toward bringing cost ... health care, MN Community Measurement has published new information about how much ...
... CHICAGO, Aug. 26 Paul S. Boulis, president ... retirement today, effective December 31, 2009. In his role ... has been responsible for all operations, including consumer and group ... medical policy, medical and disease management, government relations and public ...
... early diagnostic test , WEDNESDAY, Aug. 26 (HealthDay News) ... renal failure could offer a noninvasive and fairly inexpensive ... most treatable stages, according to Israeli researchers who developed ... volatile organic compounds in the exhaled breath of laboratory ...
Cached Medicine News:Health News:Newer, Better Tests for Heart Attacks 2Health News:Newer, Better Tests for Heart Attacks 3Health News:HCA Kicks Off 2009 'Caring for the Community' Campaign 2Health News:Morehead Presents Webinar on 'He Said…She Said: How Gender Differences Impact Physician Engagement' 2Health News:MN Community Measurement Brings Cost and Quality Information Together For Consumers 2Health News:MN Community Measurement Brings Cost and Quality Information Together For Consumers 3Health News:Paul S. Boulis, President, Blue Cross and Blue Shield of Illinois, Announces His Retirement 2Health News:'Electronic Nose' Could Spot Kidney Disease 2
...
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... The Consensus knee system continues the ... intelligent engineering with the diversified experience of ... an affordable knee system that incorporates state-of-the-art ... provide both joint and implant stability and ...
Medicine Products: